Security key
68764Y207
OS Therapies Inc - Common Stock, par value $0.001 per share (OSTX)
CUSIP: 68764Y207
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 31,500,824
- Total 13F shares
- 2,897,570
- Share change
- +1,055,634
- Total reported value
- $4,085,860
- Price per share
- $1.41
- Number of holders
- 29
- Value change
- +$1,489,526
- Number of buys
- 16
- Number of sells
- 7
Report period
Q1 2026
Institutions
29
Top holders
10
OSTX full security history
Previous quarter: Q4 2025
OS Therapies Inc SEC filings
OS Therapies Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68764Y207
Recent filing periods:
Top shareholders of OSTX - OS Therapies Inc - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals, Inc. |
13D/G
|
— |
10%
|
2,164,215
|
$4,328,430 | $0 | 09 Apr 2025 | |
| Thomas A. Satterfield Jr. |
13D/G
|
— |
9.4%
|
3,115,681
|
$5,296,658 | +$3,141,967 | 30 Jun 2025 | |
| Shalom Auerbach |
3/4/5
13D/G
|
Former 10% Owner |
8.5%
from 13D/G
|
2,687,570
|
$5,356,349 | — | 09 May 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.7%
|
540,421
|
$756,589 | — | 31 Dec 2025 | |
| CM Management, LLC |
13F
|
Company |
1.3%
|
400,000
|
$560,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.78%
|
246,038
|
$344,452 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.35%
|
109,949
|
$153,929 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.28%
|
87,537
|
$122,552 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.23%
|
71,309
|
$99,833 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.19%
|
61,425
|
$85,995 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.19%
|
58,500
|
$81,900 | — | 31 Dec 2025 | |
| INGALLS & SNYDER LLC |
13F
|
Company |
0.12%
|
36,676
|
$51,000 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.1%
|
30,785
|
$43,099 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.09%
|
27,740
|
$38,836 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.08%
|
25,000
|
$35,000 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.06%
|
18,156
|
$25,418 | — | 31 Dec 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.05%
|
15,000
|
$21,000 | — | 31 Dec 2025 | |
| Stratos Wealth Advisors, LLC |
13F
|
Company |
0.04%
|
13,817
|
$19,344 | — | 31 Dec 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0.03%
|
10,867
|
$15,214 | — | 31 Dec 2025 | |
| MERCER GLOBAL ADVISORS INC /ADV |
13F
|
Company |
0.03%
|
10,220
|
$14,308 | — | 31 Dec 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.03%
|
10,113
|
$14,158 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,000
|
$1,400 | — | 31 Dec 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
480
|
$1,000 | — | 31 Dec 2025 | |
| ARMSTRONG ADVISORY GROUP, INC |
13F
|
Company |
0%
|
100
|
$140 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
88
|
$123 | — | 31 Dec 2025 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
25
|
$35 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
23
|
$32 | — | 31 Dec 2025 | |
| Paul A. Romness |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
3,973,000
mixed-class rows
|
$3,808,420 | — | 22 Jan 2026 | |
| Colin Goddard |
3/4/5
|
Director |
—
mixed-class rows
|
625,179
mixed-class rows
|
$1,516,581 | — | 31 Dec 2024 | |
| John Ciccio |
3/4/5
|
Director |
—
mixed-class rows
|
545,835
mixed-class rows
|
$701,985 | — | 22 Jan 2026 | |
| Theodore F. Search |
3/4/5
|
Director |
—
mixed-class rows
|
545,835
mixed-class rows
|
$701,985 | — | 22 Jan 2026 | |
| Robert Petit |
3/4/5
|
Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated. |
—
mixed-class rows
|
300,000
mixed-class rows
|
$308,000 | — | 22 Jan 2026 | |
| Christopher P. Acevedo |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
409,375
mixed-class rows
|
$168,437 | — | 22 Jan 2026 | |
| Avril McKean-Dieser |
3/4/5
|
Director |
—
mixed-class rows
|
95,000
mixed-class rows
|
$7,700 | — | 22 Jan 2026 | |
| Olivier Roger Jarry |
3/4/5
|
Director |
—
mixed-class rows
|
90,000
mixed-class rows
|
— | — | 22 Jan 2026 | |
| Karim Galzahr |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 22 Jan 2026 |
Institutional Holders of OS Therapies Inc - Common Stock, par value $0.001 per share (OSTX) as of Q1 2026
As of 31 Mar 2026,
OS Therapies Inc - Common Stock, par value $0.001 per share (OSTX) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,897,570 shares.
The largest 10 holders included
VANGUARD CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CM Management, LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, HOWARD FINANCIAL SERVICES, LTD., VANGUARD FIDUCIARY TRUST CO, STATE STREET CORP, NORTHERN TRUST CORP, and BlackRock, Inc..
This page lists
29
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
24
Q1 2026 holders
29
Holder diff
5
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.